Lupin Settles Ongoing Litigation with Medicis over Generic Versions of SOLODYN
Source : AG-IP News
Visits : 7615
MUMBAI - Pharma major, Lupin Ltd. announced today in a press release that it and its subsidiary, Lupin Pharmaceuticals Inc. (collectively, “Lupin”), have settled all ongoing litigation over SOLODYN® (minocycline HCI, USP) Extended Release Tablets with Medicis Pharmaceutical Corporation (“Medicis”).
The settlement entitles Lupin to sell its generic versions of SOLODYN® in 45mg, 90mg, and 135mg strengths under a license from Medicis commencing November 2011, or earlier under certain conditions. The settlement also entitles Lupin to sell its generic versions of SOLODYN® in 65mg and 115mg strengths under a license from Medicis effective in February 2018, or earlier under certain conditions. In addition, the settlement entitles Lupin to sell its generic versions of SOLODYN® in 55mg, 80mg and 105mg strengths under a license from Medicis effective in February 2019, or earlier under certain conditions.
Headquartered in Mumbai, India, Lupin Limited is an innovation led transnational pharmaceutical company producing a wide range of generic and branded formulations and APIs. The Company today has significant presence in Cardiovasculars, Diabetology, Asthma, Pediatrics, CNS, GI, Anti-Infectives and NSAIDs in addition to holding global leadership positions in the Anti-TB and Cephalosporins space.